Measles, Mumps and Rubella Virus Vaccine Live
STN: BL 101069
Proper Name: Measles, Mumps and Rubella Virus Vaccine Live
Tradename: M-M-R II
Manufacturer: Merck Sharp & Dohme LLC
Indication:
- M-M-R II is a vaccine indicated for active immunization for the prevention of measles, mumps and rubella in individuals 12 months of age and older.
Product Information
- Package Insert - Measles, Mumps, and Rubella Virus Vaccine Live
- Patient Package Insert - Measles, Mumps, and Rubella Virus Vaccine Live
Supporting Documents
- August 21, 2023 Approval Letter - Measles, Mumps, and Rubella Virus Vaccine Live
- February 27, 2023 Approval Letter - Measles, Mumps, and Rubella Virus Vaccine Live
- February 27, 2023 Clinical Review Memo - Measles, Mumps, and Rubella Virus Vaccine Live
- Statistical Review - Measles, Mumps, and Rubella Virus Vaccine Live
- December 11, 2020 Approval Letter - Measles, Mumps, and Rubella Virus Vaccine Live
- June 19, 2020 Approval Letter - Measles, Mumps, and Rubella Virus Vaccine Live
- May 16, 2017 Approval Letter - Measles, Mumps, and Rubella Virus Vaccine Live
- Supporting Documents older than three years - MMR II